Literature DB >> 7857010

Recurrent pleomorphic adenoma of the parotid gland: report of 126 cases and a review of the literature.

P P Phillips1, K D Olsen.   

Abstract

The records of 126 patients with recurrent pleomorphic adenoma of the parotid gland treated at our institution from 1965 to 1985 were retrospectively reviewed. Multiple variables were analyzed to determine tumor behavior and treatment results. Of the study patients, 61% were female and 39% male, with a mean age of 35.6 years at the time of treatment at our institution. The average follow-up period was 14.5 years. Tumor recurrence was 32.5% after one operation at our institution, 7.1% after two operations, and 1.6% after three. Malignant disease occurred in 9 (7.1%) patients. After all surgical procedures, partial facial nerve paralysis was noted in 13.5% and total paralysis in 5.5%. These results suggest low morbidity and good success in tumor eradication with an aggressive surgical approach.

Entities:  

Mesh:

Year:  1995        PMID: 7857010     DOI: 10.1177/000348949510400203

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  13 in total

1.  Multinodular neck recurrence of parotid gland pleomorphic adenoma: a case report.

Authors:  Nick Papadogeorgakis; Evagelos F Kalfarentzos; Vassilis Petsinis; Eleni Parara; Maria-Emmanouela Kopaka
Journal:  Oral Maxillofac Surg       Date:  2011-06-10

2.  Stationary facial nerve paresis after surgery for recurrent parotid pleomorphic adenoma: a follow-up study of 219 cases in Denmark in the period 1985-2012.

Authors:  Anders Nøhr; Simon Andreasen; Marianne Hamilton Therkildsen; Preben Homøe
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-12       Impact factor: 2.503

3.  Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence.

Authors:  T Hamada; S Matsukita; M Goto; S Kitajima; S K Batra; T Irimura; K Sueyoshi; K Sugihara; S Yonezawa
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

4.  Imaging characteristics of recurrent pleomorphic adenoma of the parotid gland.

Authors:  G Moonis; P Patel; Y Koshkareva; J Newman; L A Loevner
Journal:  AJNR Am J Neuroradiol       Date:  2007-09       Impact factor: 3.825

5.  The surgical management of recurrent or residual pleomorphic adenomas of the parotid gland. Analysis and results in 40 patients.

Authors:  H Leverstein; R M Tiwari; G B Snow; J E van der Wal; I van der Waal
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 3.236

6.  Pleomorphic Adenoma Originating from Heterotopic Salivary Tissue of the Upper Neck: A Diagnostic Pitfall.

Authors:  Riccardo La Macchia; Salvatore Stefanelli; Vincent Lenoir; Nicolas Dulguerov; Jean-Claude Pache; Minerva Becker
Journal:  Case Rep Otolaryngol       Date:  2017-11-15

7.  Clinical manifestations of recurrent parotid pleomorphic adenoma.

Authors:  Myung-Whan Suh; J Hun Hah; Seong Keun Kwon; Young-Ho Jung; Tack-Kyun Kwon; Kwang Hyun Kim; Myung-Whun Sung
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-12-31       Impact factor: 3.372

8.  Radiation Therapy After Surgical Resection Improves Outcomes for Patients With Recurrent Pleomorphic Adenoma.

Authors:  Sarah E Nicholas; Wei Fu; Angela L Liang; Regina DeLuna; Luka Vujaskovic; Justin Bishop; Brandi R Page; Harry Quon; Christine Gourin; Carole Fakhry; David Eisele; Ana P Kiess
Journal:  Adv Radiat Oncol       Date:  2021-03-02

9.  Management and prognostic factors of recurrent pleomorphic adenoma of the parotid gland: personal experience and review of the literature.

Authors:  Luca Oscar Redaelli de Zinis; Michela Piccioni; Antonino Roberto Antonelli; Piero Nicolai
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-10-25       Impact factor: 2.503

10.  Synchronous unilateral basal cell adenoma of the parotid gland: A case report.

Authors:  Jin Kuang; Qian Rao; Hao Zhang; Zhigang Cheng
Journal:  Oncol Lett       Date:  2014-07-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.